BRPI0917648A2 - composição e vetor para uso na prevenção ou no tratamento de alergia à erva de santiago por tolerização, produto contendo entre três e treze polipeptídeos, formulação farmacêutica, e, método in vitro. - Google Patents
composição e vetor para uso na prevenção ou no tratamento de alergia à erva de santiago por tolerização, produto contendo entre três e treze polipeptídeos, formulação farmacêutica, e, método in vitro.Info
- Publication number
- BRPI0917648A2 BRPI0917648A2 BRPI0917648A BRPI0917648A BRPI0917648A2 BR PI0917648 A2 BRPI0917648 A2 BR PI0917648A2 BR PI0917648 A BRPI0917648 A BR PI0917648A BR PI0917648 A BRPI0917648 A BR PI0917648A BR PI0917648 A2 BRPI0917648 A2 BR PI0917648A2
- Authority
- BR
- Brazil
- Prior art keywords
- allergy
- toleration
- vector
- prevention
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
- A61K39/36—Allergens from pollen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/145—Rhabdoviridae, e.g. rabies virus, Duvenhage virus, Mokola virus or vesicular stomatitis virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Botany (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0814986A GB0814986D0 (en) | 2008-08-15 | 2008-08-15 | Peptide for il10 production |
PCT/GB2008/002779 WO2009022155A2 (en) | 2007-08-15 | 2008-08-15 | Peptide with reduced dimer formation |
PCT/GB2008/002781 WO2009022157A2 (en) | 2007-08-15 | 2008-08-15 | Peptide with improved solubility |
GB0815218A GB0815218D0 (en) | 2008-08-20 | 2008-08-20 | Ragweed peptides for vaccine |
EP09251252.4A EP2153841B2 (en) | 2008-08-15 | 2009-05-01 | Vaccine comprising Amb a 1 peptides for use in the treatment of ragweed allergy |
PCT/GB2009/001986 WO2010018378A2 (en) | 2008-08-15 | 2009-08-14 | Ragweed peptides for vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0917648A2 true BRPI0917648A2 (pt) | 2015-12-01 |
Family
ID=41090318
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0917648A BRPI0917648A2 (pt) | 2008-08-15 | 2009-08-14 | composição e vetor para uso na prevenção ou no tratamento de alergia à erva de santiago por tolerização, produto contendo entre três e treze polipeptídeos, formulação farmacêutica, e, método in vitro. |
Country Status (18)
Country | Link |
---|---|
US (3) | US8491910B2 (pt) |
EP (3) | EP2153841B2 (pt) |
JP (1) | JP5788319B2 (pt) |
KR (1) | KR20110044787A (pt) |
CN (2) | CN104710512A (pt) |
AT (1) | ATE536880T1 (pt) |
AU (1) | AU2009281013B2 (pt) |
BR (1) | BRPI0917648A2 (pt) |
CA (1) | CA2734379A1 (pt) |
DK (1) | DK2153841T4 (pt) |
EA (1) | EA201170336A1 (pt) |
ES (1) | ES2378870T5 (pt) |
HR (1) | HRP20120206T4 (pt) |
MX (1) | MX2011001619A (pt) |
PL (1) | PL2153841T5 (pt) |
PT (1) | PT2153841E (pt) |
SI (1) | SI2153841T2 (pt) |
WO (1) | WO2010018378A2 (pt) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1958645A1 (en) * | 2007-02-13 | 2008-08-20 | Biomay AG | Peptides derived from the major allergen of ragweed (Ambrosia artemisiifolia) and uses thereof |
ES2378870T5 (es) * | 2008-08-15 | 2016-02-03 | Circassia Limited | Vacuna que comprende péptidos Amb a 1 para uso en el tratamiento de alergia a ambrosía |
WO2010018384A1 (en) * | 2008-08-15 | 2010-02-18 | Circassia Limited | T-cell antigen peptide from allergen for stimulation of il-10 production |
EP3170510A1 (de) | 2010-01-14 | 2017-05-24 | Merck Patent GmbH | Varianten der gruppe 5-allergene der süssgräser mit reduzierter allergenität durch mutagenese von prolinresten |
FI20115374A0 (fi) | 2011-04-18 | 2011-04-18 | Teknologian Tutkimuskeskus Vtt Oy | Uudet hypoallergeenit |
DK2723373T3 (en) * | 2011-06-27 | 2017-09-18 | Anergis S A | OVERLAPPING ADJUSTING PEPTIDES FOR TREATMENT |
ES2623050T3 (es) * | 2012-04-16 | 2017-07-10 | Alk-Abelló A/S | Polipéptidos profilinas vegetales para su uso en inmunoterapia de alergia inespecífica |
DK2914286T3 (da) | 2012-10-30 | 2021-11-08 | Aravax Pty Ltd | Hidtil ukendte immunterapeutiske molekyler og anvendelser deraf |
DK2968528T3 (da) * | 2013-03-15 | 2022-03-28 | Sementis Ltd | Immunmodulation |
EP3049098A4 (en) | 2013-09-25 | 2017-08-16 | Aravax Pty Ltd | Novel immunotherapeutic composition and uses thereof |
WO2017179025A1 (en) | 2016-04-15 | 2017-10-19 | Alk-Abelló A/S | Epitope polypeptides of ragweed pollen allergens |
EP3295956A1 (en) | 2016-09-20 | 2018-03-21 | Biomay Ag | Polypeptide construct comprising fragments of allergens |
CN117362453B (zh) * | 2023-12-08 | 2024-02-27 | 山东硕景生物科技有限公司 | 一种Derf1重组抗原、其制备方法及应用 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5776761A (en) * | 1989-03-17 | 1998-07-07 | Immulogic Pharmaceutical Corporation | Nucleic acids encoding allergenic proteins from ragweed |
CA2049921C (en) | 1989-03-17 | 2004-06-15 | Bruce Rogers | Allergenic proteins from ragweed and uses therefor |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
WO1994001560A1 (en) | 1991-07-12 | 1994-01-20 | Immulogic Pharmaceutical Corporation | Allergenic proteins and peptides from japanese cedar pollen |
EP0636180A1 (en) | 1992-04-09 | 1995-02-01 | Immulogic Pharmaceutical Corporation | T CELL EPITOPES OF THE MAJOR ALLERGENS FROM $i(AMBROSIA ARTEMISIIFOLIA) |
JPH07257419A (ja) | 1994-03-24 | 1995-10-09 | Kubota Corp | 農作業車 |
US5968526A (en) | 1994-04-14 | 1999-10-19 | Immulogic Pharamaceutical Corporation | T cell epitopes of the major allergens from Dermatophagoides (house dust mite) |
AU4146796A (en) * | 1994-10-27 | 1996-05-23 | Immulogic Pharmaceutical Corporation | T cell epitopes of the major allergens from ambrosia artemisiifolia |
IL115744A (en) | 1994-10-27 | 2000-07-16 | Akzo Nobel Nv | Peptides comprising a subsequence of human cartilage glycoprotein - 39 |
EP1044019A1 (en) | 1998-01-09 | 2000-10-18 | Circassia Limited | Methods and compositions for desensitisation |
US6989146B2 (en) | 2000-08-09 | 2006-01-24 | The Regents Of The University Of California | Stress proteins and peptides and methods of use thereof |
ATE414534T1 (de) | 2001-12-05 | 2008-12-15 | Circassia Ltd | Immunotherapeutische methoden und systeme |
AU2003228133A1 (en) | 2002-04-22 | 2003-11-03 | Umc Utrecht Holding B.V. | Reduction of unwanted immune reactions |
GB0210741D0 (en) | 2002-05-10 | 2002-06-19 | Medical Res Council | Methods of therapy |
GB0308988D0 (en) | 2003-04-17 | 2003-05-28 | Univ Singapore | Molecule |
WO2006075253A2 (en) | 2005-01-11 | 2006-07-20 | Commissariat A L'energie Atomique | Peptides for desensitizing subjects allergic to dog hair and dander and compositions containing said peptides. |
CN101171033A (zh) * | 2005-03-04 | 2008-04-30 | 戴纳瓦克斯技术公司 | 包含具免疫刺激序列iss之寡核苷酸的疫苗:其中iss与抗原缀合并通过缓冲条件和其他赋形剂稳定 |
EP1899367A4 (en) | 2005-06-10 | 2009-06-24 | Univ Singapore | MUTANT ALLERGENS |
US20070092532A1 (en) | 2005-10-25 | 2007-04-26 | Board Of Trustees Operating Michigan State University | Arthritis vaccines and methods |
CN100457180C (zh) * | 2005-11-09 | 2009-02-04 | 浙江我武生物科技有限公司 | 用于治疗过敏性疾病的药物组合物及其制备方法 |
RU2420569C2 (ru) | 2005-11-29 | 2011-06-10 | Актогеникс Нв | Индукция толерантности к антигенам через слизистую |
AT503690A1 (de) * | 2006-06-09 | 2007-12-15 | Biomay Ag | Hypoallergene moleküle |
EP1958645A1 (en) | 2007-02-13 | 2008-08-20 | Biomay AG | Peptides derived from the major allergen of ragweed (Ambrosia artemisiifolia) and uses thereof |
WO2008139163A1 (en) | 2007-05-09 | 2008-11-20 | Circassia Limited | Prognostic assay for determining t cell response to hla antigens and use thereof in field of tissue transplantation |
GB0710529D0 (en) | 2007-06-01 | 2007-07-11 | Circassia Ltd | Vaccine |
WO2009022154A2 (en) | 2007-08-15 | 2009-02-19 | Circassia Limited | Peptide with multiple epitopes |
ES2378870T5 (es) * | 2008-08-15 | 2016-02-03 | Circassia Limited | Vacuna que comprende péptidos Amb a 1 para uso en el tratamiento de alergia a ambrosía |
-
2009
- 2009-05-01 ES ES09251252.4T patent/ES2378870T5/es active Active
- 2009-05-01 SI SI200930185T patent/SI2153841T2/sl unknown
- 2009-05-01 EP EP09251252.4A patent/EP2153841B2/en not_active Not-in-force
- 2009-05-01 DK DK09251252.4T patent/DK2153841T4/en active
- 2009-05-01 AT AT09251252T patent/ATE536880T1/de active
- 2009-05-01 PT PT09251252T patent/PT2153841E/pt unknown
- 2009-05-01 EP EP11187164A patent/EP2433639A3/en not_active Withdrawn
- 2009-05-01 PL PL09251252.4T patent/PL2153841T5/pl unknown
- 2009-05-01 EP EP11187162A patent/EP2444100A3/en not_active Withdrawn
- 2009-08-14 BR BRPI0917648A patent/BRPI0917648A2/pt not_active IP Right Cessation
- 2009-08-14 MX MX2011001619A patent/MX2011001619A/es active IP Right Grant
- 2009-08-14 KR KR1020117006048A patent/KR20110044787A/ko not_active Application Discontinuation
- 2009-08-14 AU AU2009281013A patent/AU2009281013B2/en not_active Ceased
- 2009-08-14 CN CN201510016302.2A patent/CN104710512A/zh active Pending
- 2009-08-14 US US13/057,386 patent/US8491910B2/en not_active Expired - Fee Related
- 2009-08-14 CN CN200980139316.6A patent/CN102170897B/zh not_active Expired - Fee Related
- 2009-08-14 JP JP2011522549A patent/JP5788319B2/ja not_active Expired - Fee Related
- 2009-08-14 EA EA201170336A patent/EA201170336A1/ru unknown
- 2009-08-14 WO PCT/GB2009/001986 patent/WO2010018378A2/en active Application Filing
- 2009-08-14 CA CA2734379A patent/CA2734379A1/en not_active Abandoned
-
2012
- 2012-03-02 HR HRP20120206TT patent/HRP20120206T4/hr unknown
-
2013
- 2013-06-14 US US13/917,756 patent/US9347937B2/en active Active
-
2016
- 2016-04-28 US US15/140,724 patent/US20170014505A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0917648A2 (pt) | composição e vetor para uso na prevenção ou no tratamento de alergia à erva de santiago por tolerização, produto contendo entre três e treze polipeptídeos, formulação farmacêutica, e, método in vitro. | |
Vassilopoulou et al. | Effect of in vitro gastric and duodenal digestion on the allergenicity of grape lipid transfer protein | |
Koppelman et al. | Allergenicity attributes of different peanut market types | |
CY1112655T1 (el) | Γλυκοζυλιωμενη ιl-7, παρασκευη και χρησεις | |
MY177052A (en) | Anti a beta antibody formulation | |
BRPI0811320A2 (pt) | Surfactantes reconstituídos com propriedades melhoradas | |
WO2007092772A3 (en) | Protein formulations | |
WO2005082927A3 (en) | Antihypertensive peptides | |
EA019923B1 (ru) | Композиции со сниженным образованием димеров | |
Cabrera-Chávez et al. | Maize prolamins resistant to peptic-tryptic digestion maintain immune-recognition by IgA from some celiac disease patients | |
ES2657414T3 (es) | Uso de la lactoferrina en el diagnóstico o el pronóstico de la enfermedad de Alzheimer | |
Hofer et al. | Tackling Bet v 1 and associated food allergies with a single hybrid protein | |
EA202190310A1 (ru) | Белок для лечения воспалительных заболеваний | |
Gadermaier et al. | Isoform identification and characterization of Art v 3, the lipid-transfer protein of mugwort pollen | |
NO331277B1 (no) | Farmasoytisk sammensetning omfattende polypetid/nukleinsyre for behandling av retinale degenererende sykdommer, vektor, isolert polypeptid, renset antistoff og anvendelse av polypeptid, nukleinsyre og antistoff, samt fremgangsmater og kit | |
Sabato et al. | Basophil activation reveals divergent patient-specific responses to thermally processed peanuts | |
Davies et al. | The dominant 55 kDa allergen of the subtropical Bahia grass (Paspalum notatum) pollen is a group 13 pollen allergen, Pas n 13 | |
WO2007134118A3 (en) | Protein based composition and methods of using same | |
IL177698A0 (en) | Fusion proeins comprising modified allergens of the ns-ltps family, use thereof and pharmaceutical compositions comprising the same | |
Marzban et al. | Identification of four IgE‐reactive proteins in raspberry (Rubus ideaeus L.) | |
ATE531384T1 (de) | Peptide aus dem plasminogenaktivator-hemmer 1 und ihre verwendung | |
WO2009103319A3 (en) | Ezrin, serpin b5, peroxiredoxin-2 and heat shock protein beta-1 as autoantigens for treating or detecting streptococcal diseases | |
ATE290081T1 (de) | Parietaria judaica ns-ltp-antigenvarianten, entsprechende pharmazeutische zusammensetzungen und ihre verwendung | |
WO2007052154A3 (en) | Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators | |
Sudha et al. | Stability of protease-rich Periplaneta americana allergen extract during storage: formulating preservatives to enhance shelf life |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2475 DE 12-06-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |